Director, Center for Cancer & Aging at Penn Dreamer / Developer of Systems focused on Patient-Centered Care
Princeton, NJ
Joined November 2013
- Tweets5.3K
- Following630
- Followers2.3K
- Likes12.8K
Pinned Tweet
Imagine 4 new anticancer drugs Pallituzumab, Geriatriximab, Symptomab, & Exercizumab hit the market. They should dominate the plenary sessions at ASCO & command billion-dollar revenue. But they don't because they're nonpharmacologic & shame on us.
Read our opinion piece in @JCO_ASCO
ascopubs.org/doi/full/10.120…
Ramy Sedhom, MD, FASCO retweeted
🎧 Should patients wait months for mental health support after a cancer diagnosis? Daniel C. McFarland, DO, and @ramsedhom , explain how co-located teams and warm handoffs meet distress in real time.
cancernetwork.com/view/psych…
#OncTwitter #psychoonc #PalliativeCare
Loved the opportunity to discuss whole person cancer care !
cancernetwork.com/view/psych…
Ramy Sedhom, MD, FASCO retweeted
“Chemo brain” is one of the most common things my patients ask me about. We still have no proven drug to treat it.
In our small phase II trial, breast cancer survivors with cognitive complaints took oxaloacetate for 8 weeks. Every participant who completed the study reported improvement in cognition, along with less fatigue and better physical function.
It’s an early signal, not an answer. A randomized, placebo-controlled trial is the next step.
Led by Dr. Patti Ganz, with thanks to @BCRFcure. Out now in @JCOOA_ASCO.
doi.org/10.1200/OA-26-00063 #bcsm
Ramy Sedhom, MD, FASCO retweeted
Super insightful piece. With Daniel Sentana and @CaPsurvivorship, we’ve had similar debates re the meaning of healthcare contact days in advanced prostate cancer.
"Ultimately, time is the most precious thing any person has—never more so than after a cancer diagnosis—and protecting how it is spent is a goal worth our shared effort."
Our piece - The commodification of Time Toxicity In Oncology
ascopubs.org/doi/10.1200/JCO…
"Ultimately, time is the most precious thing any person has—never more so than after a cancer diagnosis—and protecting how it is spent is a goal worth our shared effort."
Our piece - The commodification of Time Toxicity In Oncology
ascopubs.org/doi/10.1200/JCO…
Ramy Sedhom, MD, FASCO retweeted
Outstanding presentation by @minasedrakmd at @ASCO Quality Care Symposium today!
“Beyond the Guidelines: Caring for Older Adults With Cancer.”
asco.org/quality/program
#ASCOQLTY26 #GeriOnc
Ramy Sedhom, MD, FASCO retweeted
@minasedrakmd highlights the importance of translating evidence into personalized, patient-centered care for older adults with cancer.
How do we bridge the gap between recommendations and real-world practice?
#ASCOQLTY26
Ramy Sedhom, MD, FASCO retweeted
"'Tolerated' doesn't much at all". @itsnot_pink #ASCOQLTY26 on the importance of right sizing care for patients and the lived experience of cancer treatment and survivorship.
"Right-sized care starts with a conversation about what matters, right now."
Ramy Sedhom, MD, FASCO retweeted
From grant to sustainable clinical care! @ramsedhom
At #ASCOQLTY26, an integrated psychosocial oncology program in community cancer care reported 487 referrals, >97% patient satisfaction & 86% provider satisfaction
Ramy Sedhom, MD, FASCO retweeted
Amazing. The abstract is about turning a grant into sustainable clinical care. But the real story is @ramsedhom: from a trainee interested in #GeriOnc to a leader bringing personalized cancer care to community practices.
Just today, Ramy held Penn's first #GeriOnc symposium for patients, with more than 400 attendees and leaders like @DrRFreedman.
It's been a joy to watch Ramy’s career evolve at lightning speed. I can't wait to see what he and @efratdotan (who led one of the largest therapeutic older adult trials in oncology, the GIANT study) will do together at Penn. These two are a real powerhouse!!!
Proud of you, Ramy! #ASCOQLTY26 @GuerraViswanath @PC3Innovation @PennCancer @lynn_schuchter @PennMedicine
From grant to sustainable clinical care! @ramsedhom
At #ASCOQLTY26, an integrated psychosocial oncology program in community cancer care reported 487 referrals, >97% patient satisfaction & 86% provider satisfaction
Ramy Sedhom, MD, FASCO retweeted
#ASCOQC26: Piloting a pyschosocial oncology program in a community cancer center proved feasible & impactful, showing increased patient engagement/decreased anxiety, depression, stress & fatigue.
@ASCO w/ PC3I Faculty @ramsedhom & Alexandria Muench
asco.org/abstracts-presentat…
Ramy Sedhom, MD, FASCO retweeted
Join us on Tuesday, Oct. 27 for @OncLive's State of the Science Summit on breast cancer with our own @ramsedhom. Learn more and register for this in-person event: spr.ly/6011BH8V41
Ramy Sedhom, MD, FASCO retweeted
Should be required reading for all oncology trainees, by one of the oncology and @ASCO giants Dr. Joseph Jacobson
cc: @guptaarjun90 @fischmd
healthaffairs.org/doi/10.137…
Ramy Sedhom, MD, FASCO retweeted
Death and Dying | a gripping reflective piece shared through the lens of a #medstudent in a series of graphics via @AnnalsofIM
#meded
acpjournals.org/doi/10.7326/…
Glad to see the CHALLENGE trial covered in the @nytimes - hopefully, one day, payors will support when the oncologist prescribes exercizumab nytimes.com/2026/10/06/well/…
Unfortunately, we are seeing more of this everyday. I do wish health systems did more to address the existential distress of dying patients nytimes.com/2026/10/04/magaz…
Ramy Sedhom, MD, FASCO retweeted
Perhaps lessons for lung cancer? Pathologic complete response or near pCR after neoadjuvant IO in melanoma portends almost certain cure, where have we seen that before? Looking at you CheckMate 816 in lung cancer (100% cancer specific survival at 5 years if pCR) 👀 #lcsm
Big melanoma data in @NatureMedicine 👇
A pooled analysis of 1,038 patients with resectable melanoma treated before surgery. Among the 735 who received immunotherapy, 58% had little or no viable tumor left at surgery.
Those patients? ~98% alive at 5 years.
And their 5-year recurrence-free survival was similar with or without additional immunotherapy after surgery (90.8% vs 90.6%).
So if treatment already worked this well, do patients need more?
Not randomized, so prospective trials are needed. But very encouraging.
Excellent review on the treatment of early breast cancer in older adults @drsarahsam jamanetwork-com.proxy.librar…
Ramy Sedhom, MD, FASCO retweeted
Once in a while I get to read an article so good that I hope the rest of the world also reads it. Go home, drink the good wine, and read this. Superb editorial from @Prof_IanD : ascopubs.org/doi/10.1200/OP-…
Wonderful editorial on treatment of bladder cancer in older adults - "The best surgeons know when not to cut; perhaps the best medical oncologists know and should advise when systemic anticancer treatment is not the best option" ascopubs.org/doi/full/10.120…
